Abstract
Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 × 109/L vs 0.06 × 109/L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (≥ 0.15 × 109/L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC befo...Continue Reading
References
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Sep 18, 2007·Blood·Mohamed L SorrorRainer Storb
Aug 22, 2009·The Lancet Oncology·Jürgen FinkeUNKNOWN ATG-Fresenius Trial Group
Dec 5, 2012·Bone Marrow Transplantation·Y Kanda
Apr 20, 2014·Blood·Philippe ArmandWael Saber
Jan 3, 2016·The Lancet Oncology·Irwin WalkerUNKNOWN Canadian Blood and Marrow Transplant Group
Jan 7, 2016·The New England Journal of Medicine·Nicolaus KrögerFrancesca Bonifazi
Feb 10, 2016·International Journal of Hematology·Kodai KuriyamaTakahiro Fukuda
Jan 8, 2017·Journal of Cancer Research and Clinical Oncology·Osamu ImatakiMakiko Uemura
Jan 26, 2017·Journal of Hematology & Oncology·Marie Thérèse RubioArnon Nagler
Mar 24, 2017·The Lancet. Haematology·Rick AdmiraalJaap J Boelens
Jun 7, 2017·The Lancet. Haematology·Jürgen FinkeGerard Socie
Aug 20, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Adam BryantNatasha Kekre
Sep 3, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vanessa E KennedyMadan Jagasia
Oct 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J SoifferYi-Bin Chen
Nov 13, 2017·Transplant Immunology·Souichi ShiratoriTakanori Teshima
Dec 5, 2017·Leukemia & Lymphoma·Anand TandraLeland Metheny
Jan 18, 2018·Bone Marrow Transplantation·Takafumi ShichijoTakahiro Fukuda
Feb 3, 2019·The Lancet. Haematology·Francesca BonifaziNicolaus Kröger
Aug 23, 2019·Bone Marrow Transplantation·Takafumi ShichijoBipin N Savani
Feb 1, 2020·The Lancet. Haematology·Olaf PenackGrzegorz W Basak
Mar 14, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Francine HeelanNatasha Kekre
Apr 14, 2020·Leukemia & Lymphoma·Luke MountjoyJeanne Palmer
Jun 21, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Go-Un WooSung-Soo Yoon
Jul 7, 2020·Bone Marrow Transplantation·Souichi ShiratoriUNKNOWN Japan Study Group for Cell Therapy and Transplantation (JSCT)